Article Text

Download PDFPDF
Ovarian cancer screening in the general population: current status
  1. U. Menon1 and
  2. I. J. Jacobs1,2
  1. 1Gynaecology Cancer Research Unit and
  2. 2Department of Obstetrics and Gynaecology, St. Bartholomew's and the Royal London Medical and Dental School, London, United Kingdom
  1. Address correspondence and reprint requests to: Usha Menon MD, MRCOG, Senior Lecturer, Gynaecology Cancer Research Unit, St. Bartholomew's and the Royal London Medical School, Charterhouse Square, London EC1M 6GR, UK. Email: u.menon{at}


There has been considerable interest in the prospect of early detection of ovarian cancer through screening asymptomatic women from the general population. The results of recently published trials provide encouraging data on the possible impact on mortality. There are, however, concerns about compliance, cost, and morbidity from surgery for false positive screen results. The two ongoing randomized controlled trials in the US and UK aim to establish definitively the true impact of screening on ovarian cancer mortality while comprehensively tackling the issues of target population, compliance, health economics, and physical and psychological morbidity of screening.

  • ovarian neoplasm/cancer
  • population screening
  • RCT

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.